With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market.

It includes lyophilisation, aseptic filling and manufacturing of oral solid doses, enhancing Jabil's ability to meet the clinical and commercial drug manufacturing needs of healthcare customers.

Meanwhile, Jabil’s market share has declined slightly from 5.3% in 2027 to 4.9% in 2024. We noted that Jabil’s revenue in 2024 has experienced the highest decline among competitors ...

Jabil (JBL) announced the acquisition of Pharmaceutics International, completed February 3. “Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best ...

Mexican National Guard troops and Chihuahua state police officers on Tuesday conducted a search for a possible second illegal tunnel from Juarez to El Paso, Texas. An old drainage tunnel was found, ...

Nordson Electronics Solutions, a global leader in electronics manufacturing technologies, has been honored with the 2024 Jabil Best Strategic Supplier Award, underscoring Nordson’s essential ...

"It just gives us global scale overnight," he said. Jabil is a national health care giant with over 138,000 employees, including 48,000 in North America, and revenue of $28.9 billion last year ...

The former Kmart lot on Western Boulevard has seen better days. It has been seven years since the store closed and even longer since it was bustling with shoppers. Soon, the space will be home to ...